Fmr LLC Sells 3,779,120 Shares of Moderna, Inc. (NASDAQ:MRNA)

Fmr LLC reduced its stake in Moderna, Inc. (NASDAQ:MRNA) by 17.9% during the third quarter, HoldingsChannel reports. The firm owned 17,382,165 shares of the company’s stock after selling 3,779,120 shares during the quarter. Fmr LLC’s holdings in Moderna were worth $1,161,650,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Commerzbank Aktiengesellschaft FI boosted its position in Moderna by 1.7% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock valued at $660,000 after buying an additional 93 shares in the last quarter. CVA Family Office LLC lifted its stake in shares of Moderna by 21.6% in the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company’s stock valued at $64,000 after acquiring an additional 96 shares during the last quarter. Claro Advisors LLC boosted its holdings in shares of Moderna by 2.0% during the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock valued at $659,000 after acquiring an additional 108 shares in the last quarter. McAdam LLC grew its position in Moderna by 1.1% during the 2nd quarter. McAdam LLC now owns 11,075 shares of the company’s stock worth $1,315,000 after acquiring an additional 117 shares during the last quarter. Finally, 180 Wealth Advisors LLC increased its holdings in Moderna by 1.1% in the 2nd quarter. 180 Wealth Advisors LLC now owns 14,868 shares of the company’s stock worth $1,826,000 after purchasing an additional 160 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on MRNA. Leerink Partners reduced their price target on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a report on Tuesday, September 17th. TD Cowen reduced their target price on shares of Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a report on Friday, September 13th. The Goldman Sachs Group decreased their price target on shares of Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research report on Monday, September 16th. UBS Group cut their price target on shares of Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Finally, Berenberg Bank began coverage on Moderna in a report on Tuesday, November 19th. They issued a “hold” rating and a $42.00 price objective for the company. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Moderna currently has a consensus rating of “Hold” and a consensus target price of $83.26.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. The trade was a 7.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last three months, insiders have sold 1,147 shares of company stock valued at $76,245. 15.70% of the stock is owned by company insiders.

Moderna Stock Up 3.2 %

Moderna stock opened at $43.39 on Thursday. The company has a market capitalization of $16.70 billion, a PE ratio of -7.46 and a beta of 1.69. Moderna, Inc. has a 12-month low of $35.80 and a 12-month high of $170.47. The firm’s fifty day moving average is $53.32 and its 200 day moving average is $92.28. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.39) earnings per share. As a group, sell-side analysts predict that Moderna, Inc. will post -9.44 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.